

Certificate of Analysis

MEK Inhibitor U0126:

Part No. V112A
Size 5 × 1mg

Description: MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits the kinase activity of MAP Kinase Kinase (MAPKK or MEK). It has been used in both in vivo and in vitro studies of MEK (1–6).

Formula Weight: 426.5 Daltons.

Reconstitution: MEK Inhibitor U0126 is supplied as dried material. Resuspend 1mg of U0126 (one vial) in 234µl of DMSO and vortex vigorously for 30 seconds to produce a stock solution of 10mM. Further dilutions can be carried out in DMSO. Once resuspended in DMSO, store at –20°C. The resuspended product is stable for no more than one week (6).

Storage Conditions: See the Product Information Label for storage recommendations. Avoid multiple freeze-thaw cycles or exposure to frequent temperature changes. These fluctuations can greatly alter product stability.

Part# 9PIV112

Revised 7/13



AF9PI V112 0713V112

Quality Control Assays

Identity: The chemical identity and the isomeric purity of MEK Inhibitor U0126 is confirmed by proton NMR spectroscopy. Purity is checked by elemental analysis.



Promega

Promega Corporation

2800 Woods Hollow Road	
Madison, WI 53711-5399	USA
Telephone	608-274-4330
Toll Free	800-356-9526
Fax	608-277-2516
Internet	www.promega.com

References

1. DeSilva, D.R. *et al.* (1998) Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. *J. Immunol.* **160**, 4175–81.
2. Favata, M. *et al.* (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J. Biol. Chem.* **273**, 18623–32.
3. Goueli, S. *et al.* (1998) A novel, selective and potent inhibitor of MAP Kinase Kinase (MEK). *Promega Notes* **69**, 6–8.
4. Tolwinski, N.S. *et al.* (1999) Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression. *J. Biol. Chem.* **274**, 6168–74.
5. Fredric, C. *et al.* (1999) Induction of low density lipoprotein receptor transcription by Oncostain M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter. *J. Biol. Chem.* **274**, 6747–53.
6. Duncia, J.V. *et al.* (1998) MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. *Bioorg. Med. Chem. Lett.* **8**, 2839–44.

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

Promega manufactures products for a number of intended uses. Please refer to the product label for the intended use statements for specific products. Promega products contain chemicals which may be harmful if misused. Due care should be exercised with all Promega products to prevent direct human contact.

Each Promega product is shipped with documentation stating specifications and other technical information. Promega products are warranted to meet or exceed the stated specifications. Promega's sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Promega makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO PROMEGA PRODUCTS. In no event shall Promega be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Promega products to perform in accordance with the stated specifications.

Anti-ACTIVE is a registered trademark of Promega Corporation.

© 1998–2000, 2002, 2005, 2007, 2013 Promega Corporation. All Rights Reserved.

All specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Signed by:


J. Stevens, Quality Assurance

Part# 9PIV112
Printed in USA. Revised 7/13

1. Example Protocol

The protocol given below has been used successfully at Promega to demonstrate the inhibitory effect of MEK Inhibitor U0126 on ERK1/2 signaling cascade in the presence of NGF (1). However, this procedure is not performed as a quality control assay on each batch of the MEK Inhibitor U0126 and will require optimization depending on the experimental conditions used.

Inhibitory effect of U0126 on ERK1/2 signaling cascade in the presence of NGF.



PC12 cells were grown in serum-free RPMI medium for 16 hours. The inhibitor U0126 was added to the medium at 10 μ M in 0.2% DMSO for 15 minutes. Nerve growth factor (NGF) was then added at a final concentration of 50ng/ml, and the cells were incubated for either 5 or 30 minutes before harvesting and lysing. Protein samples (20 μ g) were analyzed by SDS-PAGE and Western blot. Detection was performed with Anti-ERK 1/2 pAb (Cat.# V1141) and Anti-ACTIVE[®] MAPK pAb (Cat.# V8031) using the Tropix chemiluminescence detection system. **Panel A.** The amount of total ERK1/2 shows little change with the various treatments, as detected by the Anti-ERK 1/2 pAb. **Panel B.** Using Anti-ACTIVE[®] MAPK pAb, which recognizes only the active ERK1/2, it is shown that U0126 completely inhibits the activation of ERK1/2 in NGF-treated PC12 cells at both 5 and 30 minutes. Lane 1, no NGF; lane 2, NGF for 5 minutes; lane 3, NGF for 30 minutes; lane 4, U0126; lane 5, U0126 + NGF for 5 minutes; lane 6, U0126 + NGF for 30 minutes.

2. Related Products

Product	Size	Cat.#
Anti-ACTIVE [®] MAPK pAb, Rabbit (pTEpY)	40 μ l	V8031
Anti-ACTIVE [®] JNK pAb, Rabbit (pTPpY)	40 μ l	V7931
	120 μ l	V7932
Anti-ACTIVE [®] p38 pAb, Rabbit (pTGpY)	100 μ l	V1211
Anti-ERK 1/2 pAb, Rabbit	40 μ l	V1141
Donkey Anti-Rabbit IgG, HRP, Anti-ACTIVE [®] Qualified	60 μ l	V7951
SB 203580 (p38 Inhibitor)	1mg	V1161
PD 98059 (MEK Inhibitor)	5mg	V1191

3. Reference

- Goueli, S.A. *et al.* U0126: A novel, selective and potent inhibitor of MAP Kinase (MEK). *Promega Notes* **69**, 6–8.